Loading
Ferroptosis and Cancer Prognosis · Journal article
Cancers · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study demonstrates that HSP90AA1 knockdown enhances doxorubicin sensitivity in breast cancer cells and reduces tumor burden in a mouse model, accompanied by increased immunogenic cell death markers and immune infiltration. The findings are mechanistically coherent but remain in the experimental stage, without human efficacy data or clinical translation.
Preclinical mechanistic study: in vitro knockdown experiments and syngeneic mouse tumor model with bioinformatic analysis. Breast cancer cell lines and female mice bearing 4T1 syngeneic breast cancers; no human subjects enrolled.. Intervention: HSP90AA1 knockdown (method not specified in abstract) combined with doxorubicin treatment. Compared with: Doxorubicin treatment alone; HSP90AA1 knockdown without doxorubicin status unclear.
HSP90AA1 upregulated in breast cancer and associated with unfavorable survival in bioinformatic analyses HSP90AA1 knockdown increased cleaved-caspase-3 and BAX, decreased BCL-2 in vitro HSP90AA1 knockdown with DOX increased CALR, HMGB1, p-eIF2α/eIF2α in vitro
Human efficacy, toxicity, and pharmacokinetic data entirely absent
These findings suggest a potential therapeutic strategy but remain at the preclinical stage. Clinical translation would require mechanistic validation in human tumors and subsequent phase 1/2 trials before clinical adoption.
Experimental validation in cell lines and a single syngeneic mouse model of a candidate target, lacking human efficacy data, phase 1 trial, or clinical translation to support practice change.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest a potential therapeutic strategy but remain at the preclinical stage. Clinical translation would require mechanistic validation in human tumors and subsequent phase 1/2 trials before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Doxorubicin (DOX) is widely used in breast cancer treatment; however, therapeutic resistance and an immunosuppressive tumor microenvironment remain major obstacles to effective therapy. Immunogenic cell death (ICD) contributes to chemotherapy-induced antitumor immunity, but the molecular regulators linking DOX response, ICD-related signaling, and immune infiltration in breast cancer remain incompletely understood. This study aimed to identify and experimentally validate HSP90AA1 as a potential regulator of DOX response and ICD-associated immune remodeling in breast cancer. Methods: ICD-related genes were analyzed using public breast cancer transcriptomic datasets to construct prognostic models and evaluate their associations with survival, immune infiltration, immune checkpoint expression, and HLA-related molecules. HSP90AA1 was selected as a candidate gene for further validation. HSP90AA1 expression was examined in breast cancer tissues and cell lines. HSP90AA1 knockdown was performed in breast cancer cells, followed by DOX treatment. Western blotting was used to detect apoptosis-related proteins, ICD-related markers, and immune-associated molecules, including cleaved-caspase-3, BAX, BCL-2, CALR, HMGB1, p-eIF2α/eIF2α, and PD-L1. In vivo, a 4T1 syngeneic breast cancer mouse model was established to assess the effects of HSP90AA1 knockdown combined with DOX on tumor growth and tumor immune-related protein expression. Results: Bioinformatic analyses showed that ICD-related molecular patterns were associated with prognosis and immune microenvironment features in breast cancer. HSP90AA1 was upregulated in breast cancer and associated with unfavorable survival, supporting its potential relevance as an ICD-related prognostic candidate. In vitro, HSP90AA1 knockdown enhanced DOX-induced apoptotic responses, as indicated by increased cleaved-caspase-3 and BAX expression and decreased BCL-2 expression. HSP90AA1 knockdown also strengthened DOX-induced ICD-related molecular changes, including increased CALR, HMGB1, and p-eIF2α/eIF2α levels, accompanied by altered PD-L1 expression. In vivo, Hsp90aa1 knockdown combined with DOX resulted in a greater reduction in terminal tumor burden than DOX treatment alone. Tumor tissues from the combination group showed increased CALR, HMGB1, CD8A, and GZMB expression, together with altered PD-L1 expression. Tumor tissues from the combination group showed increased CALR, HMGB1, CD8A, and GZMB expression, together with altered PD-L1 expression, indicating ICD-related and immune-associated molecular changes. Conclusions: This study identifies HSP90AA1 as a potential ICD-related regulator of DOX response in breast cancer. HSP90AA1 knockdown may enhance the response to DOX by promoting apoptotic responses and ICD-related molecular changes, together with immune-related tumor microenvironment remodeling. These findings provide experimental evidence supporting HSP90AA1 as a potential therapeutic target for improving chemotherapy response in breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.